Basic Information
| LncRNA/CircRNA Name | KRAL |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | 5-fluorouracil | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | mircoarray, qPCR, RIP, Dual Luciferase Reporter Assay, Western blot |
| Sample | hepatocellular carcinoma tissues, cell lines(HepG2, SMMC-7721) |
| Expression Pattern | down-regulated |
| Function Description | KRAL expression is downregulated in 5-fluorouracilresistant HCC cells, KRAL functioned as a competitive endogenous RNA (ceRNA) by effectively binding to the common miR-141 and then restoring Keap1 expression. the ceRNA network involving KRAL may serve as a treatment strategy against 5-FU resistance in hepatocellular carcinoma cells. The results indicated that compared with control cells, cells with KRAL overexpression exhibited a reversal in the resistance against 5-FU, with a significant decrease in the IC50 and a dramatic increase in cellular apoptosis. |
| Pubmed ID | 30119680 |
| Year | 2018 |
| Title | lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. |
External Links
| Links for KRAL | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |